Canadian researchers assessed whether exposure to wildfire-related fine particulate matter was associated with ED visits for migraine and other headaches.
A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
In a cross-sectional questionnaire study of 106 adults with migraine, vomiting-induced migraine pain relief occurred in 54.9% of patients who vomited during attacks, with some reporting pain relief within...
A phase 3 randomized trial evaluated the efficacy and safety of fremanezumab for preventive treatment of episodic migraine in children and adolescents, addressing a significant evidence gap in pediatric...
In a resting-state fMRI study of adults with episodic migraine, chronic migraine, and healthy controls, migraine was associated with reduced brain entropy, with partial entropy restoration during attacks.
...
Featured faculty at The Revolution & Paradigm Shift in Treatment of Migraine, scheduled for July 16-17, 2026, will highlight evolving approaches to migraine diagnosis, prevention, disease burden, and...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, addressed migraine-related diagnosis, treatment, red flags, and care considerations across...
